HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17

Benzinga · 07/07 11:41
HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.